A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). (Q45272587)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). |
scientific article |
Statements
1 reference
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). (English)
1 reference
Rabab M Gaafar
1 reference
Veerle F Surmont
1 reference
Giorgio V Scagliotti
1 reference
Rob J Van Klaveren
1 reference
Demetris Papamichael
1 reference
John J Welch
1 reference
Baktiar Hasan
1 reference
Valter Torri
1 reference
Jan P van Meerbeeck
1 reference
EORTC Lung Cancer Group and the Italian Lung Cancer Project
1 reference
28 July 2011
1 reference
1 reference
47
1 reference
15
1 reference
2331-2340
1 reference
Identifiers
1 reference
1 reference